Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $545.80, for a total value of $5,185,100.00. Following the completion of the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $22,111,995.40. This represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

United Therapeutics Stock Performance

UTHR stock opened at $547.15 on Thursday. The stock’s 50 day simple moving average is $559.06 and its 200 day simple moving average is $527.20. The company has a market cap of $23.22 billion, a P/E ratio of 20.20, a price-to-earnings-growth ratio of 1.78 and a beta of 0.57. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company’s revenue was down 1.6% on a year-over-year basis. During the same period last year, the business posted $6.63 EPS. Equities analysts predict that United Therapeutics Corporation will post 26.63 earnings per share for the current year.

Wall Street Analysts Forecast Growth

UTHR has been the topic of several research reports. Bank of America upped their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. HC Wainwright boosted their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Raymond James Financial started coverage on shares of United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price on the stock. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Finally, UBS Group lifted their price target on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Geneos Wealth Management Inc. increased its stake in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in shares of United Therapeutics by 18.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after buying an additional 70 shares during the last quarter. Jump Financial LLC bought a new position in shares of United Therapeutics in the second quarter valued at approximately $277,000. Cerity Partners LLC grew its holdings in shares of United Therapeutics by 77.3% in the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after acquiring an additional 5,600 shares in the last quarter. Finally, Bank of Nova Scotia increased its position in shares of United Therapeutics by 6.9% during the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 105 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.